Reviewing Vaxart (VXRT) and Its Competitors

Vaxart (OTCMKTS:VXRT) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Vaxart to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

18.0% of Vaxart shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.8% of Vaxart shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Vaxart and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	16.02%	35.14%	17.10%
Vaxart Competitors	-2,380.39%	-218.78%	-15.59%

Valuation & Earnings

This table compares Vaxart and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vaxart	$237.26 million	$16.33 million	2.88
Vaxart Competitors	$5.43 billion	$3.22 billion	552.60

Vaxart’s competitors have higher revenue and earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Vaxart has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Vaxart’s competitors have a beta of -3.79, suggesting that their average share price is 479% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vaxart and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	1	0	0	2.00
Vaxart Competitors	7798	13891	25788	1038	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.59%. Given Vaxart’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Vaxart has less favorable growth aspects than its competitors.

Summary

Vaxart competitors beat Vaxart on 9 of the 13 factors compared.

Vaxart Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.